ClinicalTrials.gov · NCT05835999 · Completed
Everolimus Aging Study
Registry record
NCT05835999 on ClinicalTrials.gov. The registry's last update to this record was 4 September 2026.
Verification record
5 checked · 0 company says · 0 reported · 0 not found · 0 not yet checked
- Title as registered Everolimus Aging Study Checked Source clinicaltrials.gov Brief title as registered. Checked
- Sponsor University of Wisconsin, Madison Checked Source clinicaltrials.gov Lead sponsor as registered. Checked
- Intervention Everolimus 0.5 MG once per day; Everolimus 5 MG once per week; Placebo once per day; Placebo once per week Checked Source clinicaltrials.gov Intervention names as registered. Checked
- Primary outcome as registered Metabolic Function: Change in peripheral insulin sensitivity Checked Source clinicaltrials.gov Primary outcome measure(s) as registered. Checked
- Status Completed Checked Source clinicaltrials.gov Overall status as registered; registry last update 2026-09-04. Checked
Check history: NCT05835999 was last read on the registry on November 14, 2026. No earlier checks are recorded. How records are checked.
Corrections: none recorded for this trial. To ask for one, write to [email protected] with the registry number; every correction is checked against the registry record before the record changes.
As registered
- Sponsor: University of Wisconsin, Madison
- Phase: Phase 2
- Status: Completed
- Intervention: Everolimus 0.5 MG once per day; Everolimus 5 MG once per week; Placebo once per day; Placebo once per week
- Primary outcome: Metabolic Function: Change in peripheral insulin sensitivity
- Countries: United States
- Start: 24 March 2023
- Completion (actual): 22 July 2026
Results
No results were posted on the registry on the date checked. The Atlas does not summarize findings.
Related modality